Published in Neuroreport on December 09, 2009
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2014) 1.53
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res (2015) 1.01
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J (2014) 0.88
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget (2015) 0.86
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release (2016) 0.76
PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy (2014) 0.76
The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf (2016) 0.75
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients. J Pathol Transl Med (2016) 0.75
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. Front Pharmacol (2017) 0.75
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) (2003) 2.48
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev (1995) 1.51
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
PTEN methylation and expression in glioblastomas. Acta Neuropathol (2003) 1.31
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood (2004) 1.25
Transcriptional responses of murine macrophages to infection with Yersinia enterocolitica. Cell Microbiol (2004) 1.08
B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport (2005) 1.05
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology (2005) 1.03
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Sensitivity of noncontrast cranial computed tomography for the emergency department diagnosis of subarachnoid hemorrhage. Ann Emerg Med (2008) 3.76
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg (2010) 2.19
Modern surgical outcomes following surgery for sphenoid wing meningiomas. J Neurosurg (2013) 2.16
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Complications of lumboperitoneal shunts. Neurosurgery (2007) 2.07
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg (2010) 1.74
Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg (2010) 1.72
The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg (2010) 1.67
Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg (2010) 1.67
Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg (2011) 1.67
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg (2008) 1.66
Cancer and the complement cascade. Mol Cancer Res (2010) 1.64
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg (2012) 1.64
The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci (2009) 1.62
Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg (2009) 1.59
Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review. J Neurosurg Pediatr (2012) 1.57
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. J Neurosurg (2010) 1.55
Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. J Neurosurg (2013) 1.55
Atypia predicting prognosis for intracranial extraventricular neurocytomas. J Neurosurg (2011) 1.54
Extent of resection and the long-term durability of vestibular schwannoma surgery. J Neurosurg (2011) 1.53
Risk factors for the development of serious medical complications after resection of meningiomas. Clinical article. J Neurosurg (2010) 1.53
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res (2006) 1.52
Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine (2013) 1.51
Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg (2015) 1.48
Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg (2010) 1.48
A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg (2010) 1.46
Gliomas: advances in molecular analysis and characterization. Surg Neurol (2005) 1.46
What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients? J Neurosurg (2014) 1.44
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res (2005) 1.42
Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg (2010) 1.38
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer (2011) 1.35
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus (2011) 1.33
Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg (2009) 1.32
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res (2005) 1.28
Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg (2010) 1.28
Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology (2010) 1.28
Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun (2013) 1.26
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci (2010) 1.26
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg (2005) 1.25
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol (2009) 1.25
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol (2003) 1.24
Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery (2005) 1.24
The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res (2009) 1.22
Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res (2004) 1.19
S6K1 plays a key role in glial transformation. Cancer Res (2008) 1.16
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2012) 1.15
FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res (2010) 1.14
The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res (2010) 1.14
Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am (2012) 1.13
Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery (2012) 1.13
A systematic review of intracranial chondrosarcoma and survival. J Clin Neurosci (2009) 1.13
Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease. J Neurosurg Spine (2012) 1.11
A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. J Neurosurg (2010) 1.11
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol (2005) 1.09
A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors. J Neurosurg (2010) 1.07
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol (2009) 1.06
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol Cancer Ther (2006) 1.06
Cranial chondrosarcoma and recurrence. Skull Base (2010) 1.06
Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus (2010) 1.05
Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol (2013) 1.04
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res (2006) 1.04